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Abstract
Objective
To assess the performance of symptom-based screening for tuberculosis (TB), alone and
with chest radiography among people living with HIV (PLHIV), including pregnant women, in
Western Kenya.
Design
Prospective cohort study
Methods
PLHIV from 15 randomly-selected HIV clinics were screened with three clinical algorithms
[World Health Organization (WHO), Ministry of Health (MOH), and “Improving Diagnosis of
TB in HIV-infected persons” (ID-TB/HIV) study], underwent chest radiography (unless preg-
nant), and provided two or more sputum specimens for smear microscopy, liquid culture,
and Xpert MTB/RIF. Performance of clinical screening was compared to laboratory results,
controlling for the complex design of the survey.
Results
Overall, 738 (85.6%) of 862 PLHIV enrolled were included in the analysis. Estimated TB
prevalence was 11.2% (95% CI, 9.9–12.7). Sensitivity of the three screening algorithms
was similar [WHO, 74.1% (95% CI, 64.1–82.2); MOH, 77.5% (95% CI, 68.6–84.5); and ID-
TB/HIV, 72.5% (95% CI, 60.9–81.7)]. Sensitivity of the WHO algorithm was significantly
lower among HIV-infected pregnant women [28.2% (95% CI, 14.9–46.7)] compared to non-
pregnant women [78.3% (95% CI, 67.3–86.4)] and men [77.2% (95% CI, 68.3–84.2)]. Chest
radiography increased WHO algorithm sensitivity and negative predictive value to 90.9%
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(95% CI, 86.4–93.9) and 96.1% (95% CI, 94.4–97.3), respectively, among asymptomatic
men and non-pregnant women.
Conclusions
Clinical screening missed approximately 25% of laboratory-confirmed TB cases among all
PLHIV and more than 70% among HIV-infected pregnant women. National HIV programs
should evaluate the feasibility of laboratory-based screening for TB, such as a single Xpert
MTB/RIF test for all PLHIV, especially pregnant women, at enrollment in HIV services.
Introduction
Tuberculosis (TB) remains the leading preventable cause of morbidity and mortality among
people living with HIV (PLHIV) [1]. In 2015, 1.2 million (11%) of 10.4 million people who
developed TB were HIV-infected, and 390,000 deaths among PLHIV with TB accounted for
more than one-fifth of all TB-associated deaths. More than 35% of all HIV-related TB deaths
in 2015 occurred in women [2]. If not adequately controlled, TB has the potential to under-
mine the great strides made globally in rapidly expanding life-saving HIV care and treatment.
TB intensified case finding (ICF) is a critical component of the World Health Organization
(WHO) recommendations for TB/HIV collaborative activities [3].
In 2010, WHO conducted meta-analysis of existing data on TB screening among PLHIV in
2010 in order to identify an evidence-based clinical screening algorithm. This meta-analysis
identified the presence of current cough of any duration, fever, night sweats, or weight loss as
the best performing screening rule, with an overall sensitivity of 78.9% for TB among all
PLHIV and 90.1% among those screened in clinical settings and a negative predictive value of
95.3% among PLHIV with a 10% prevalence of TB [4]. Based on this evidence, WHO recom-
mends use of this algorithm for screening PLHIV at every clinical encounter [5]. At the time
of study implementation, limited data were available about the performance of the WHO algo-
rithm in sub-Saharan Africa. Although a few prospective studies have since evaluated the per-
formance of the WHO clinical screening algorithm for TB among PLHIV, the majority of
studies have not assessed implementation of screening by healthcare workers routinely provid-
ing care to PLHIV and even fewer have assessed the performance of screening among preg-
nant women [6–11]. In this paper, we describe our evaluation of the performance of routine
TB ICF algorithms among PLHIV newly enrolling in HIV services, including prevention of
mother-to-child HIV transmission (PMTCT) services, in a high HIV and TB burden region of
Western Kenya.
Methods
Study Design and Participants
We conducted a prospective cohort study in Western Kenya to evaluate the performance of
clinical screening for TB among adults and older children living with HIV using the WHO TB
ICF algorithm [5]. Additionally, we evaluated the performance of the 2009 Kenya Ministry of
Health (MOH) ICF algorithm, which was the standard of care for clinical screening in Kenya
at the time of this study, and we evaluated the performance of the screening algorithm derived
from the “Improving Diagnosis of TB in HIV-infected persons” (ID-TB/HIV) study of PLHIV
in three countries in Southeast Asia [12, 13]. The ID-TBHIV study algorithm was one of the
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first evidence-based clinical screening algorithms for TB among PLHIV, but the performance
of the algorithm in sub-Saharan Africa was unknown.
Detailed study procedures have been described elsewhere [14]. Briefly, the sample frame
included all public HIV care and treatment facilities (including associated PMTCT services)
with at least 200 enrolled patients in the Siaya, Bondo, and Kisumu East Districts of the Nyanza
Province. Sites were divided into two strata: small (200–1000 patients; N = 14) and large
(>1000 patients; N = 10). Participants were recruited from 15 randomly selected HIV clinics
(6 large and 9 small). The number of sites selected from each stratum was proportional to the
size of the stratum. Our target sample size was 1000 participants, which accounted for loss to
follow-up and was calculated using the Clopper-Pearson method based on assumptions of an
expected false-negative screening frequency of 3% based on ID-TB/HIV study findings [12].
Enrollment occurred in a phased manner between May 2011 and June 2012, with each clinical
site enrolling participants for 10 weeks. Inclusion criteria were documented HIV infection
based on Kenya national guidelines [15], age 7 years or older, and willingness to participate in
the study. Exclusion criteria were receipt of any HIV-related care in the preceding two years
and TB treatment at enrollment or at any time in the previous one year. Children younger
than age 7 years were excluded because of challenges with spontaneous sputum expectoration
and the need for alternative diagnostic investigations in this population.
Clinical Screening and Evaluation for TB
All PLHIV received standard medical care per Kenya MOH guidelines, which included TB
screening at entry into care using the 2009 Kenya MOH ICF algorithm [cough 2 weeks, his-
tory of close contact with person with confirmed TB or chronic cough, fever 2 weeks, notice-
able weight loss, chest pain or breathlessness, night sweats2 weeks, swelling in neck, armpit,
abdomen, joints or groin] a physical examination, and CD4 count analysis to determine anti-
retroviral treatment (ART) eligibility [13, 16, 17]. Additionally, all PLHIV were screened for
TB at enrollment using the WHO screening algorithm [current cough, fever in the previous 4
weeks, night sweats in the previous 4 weeks, or weight loss in the previous 4 weeks] and an
algorithm derived from the “Improving Diagnosis of TB in HIV-infected persons” (ID-TB/
HIV) study of PLHIV in three countries in Southeast Asia [any cough in previous 4 weeks, any
fever in the previous 4 weeks, or night sweats lasting longer than 3 weeks] [5, 17]. After the
clinical screening and regardless of symptoms, PLHIV were referred for chest radiography and
asked to provide three sputum specimens within 14 days, including one morning and two spot
specimens; specimens were collected over the course of two days. In accordance with local
clinical practice, pregnant women were excluded from receiving chest radiography. All medi-
cal care, including TB screening, interpretation of chest radiographs, and treatment decisions,
was provided in accordance with standard clinical practice by a combination of physicians and
non-physicians who were routinely working at the HIV care and treatment facilities. Our
study involved assessment for TB disease only; alternative diagnoses were investigated as part
of routine medical services and were not captured as part of this study.
Laboratory Procedures
Sputum specimens were collected at study sites and transported to the Kenya Medical
Research Institute (KEMRI)/U.S. Centers for Disease Control and Prevention (CDC) reference
laboratory for smear microscopy, mycobacterial culture, and Xpert MTB/RIF (Cepheid Inc.,
Sunnyvale, CA, USA) [18]. Laboratory personnel were not aware of the clinical signs or symp-
toms of the individuals who produce the sputum. Xpert MTB/RIF was performed on a 1 ml ali-
quot of the morning sputum specimen and on the entire second spot specimen (up to 4 mls
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per manufacturer recommendations). The first spot sputum specimen and the remainder of
the morning sputum specimen were cultured using the BACTEC Mycobacteria Growth Indi-
cator Tube (MGIT) 960 system (Becton Dickinson, Sparks, MD, USA) using methods previ-
ously described [19]. Positive cultures were identified as Mycobacterium tuberculosis complex
(MTBC) by Ziehl-Neelson acid fast bacilli (AFB) microscopy and either the Capilia TB Neo
(Tauns Laboratories, Inc., Shizuoka, Japan) or the MGIT TBc ID (Becton Dickinson, Sparks,
MD, USA) immunochromatographic assay. The Hain Genotype CM line probe assay (Hain
Lifescience, Nehren, Germany) was used to further identify culture isolates with non-tubercu-
lous mycobacteria.
Definitions
PLHIV who reported any symptom or sign in the algorithm suggestive of TB were defined as
having “presumptive TB” (previously known as a “TB suspect”) by that algorithm [20]. PLHIV
who did not submit at least two sputum specimens or who did not have at least two valid
results were excluded. Invalid test results were defined as a contaminated culture or an Xpert
MTB/RIF result of error, invalid, or no result. Among the remaining PLHIV, a pulmonary TB
case was defined as any person with MTBC confirmed by at least one Xpert MTB/RIF or liquid
culture test. PLHIV for whom no sputum specimens were positive for MTBC by Xpert MTB/
RIF or liquid culture were considered not to have TB.
Data Collection and Analysis
Demographic information, clinical symptom screening, and physical examination findings
were documented in paper-based medical records by clinicians at each site. Study personnel
entered these data into an SQL database, which was merged with the KEMRI/CDC laboratory
SQL database. Data were analyzed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA)
and Stata 13.1 (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: Sta-
taCorp LP). Symptom screening results were reviewed and recoded for internal consistency so
that, for example, patients reporting cough lasting for 2 weeks or longer were also reported as
having any cough. We calculated the sensitivity, specificity, negative predictive value, and posi-
tive and negative likelihood ratios of the three TB screening algorithms [WHO, MOH and
ID-TB/HIV] compared to laboratory-confirmed pulmonary TB. Analyses were weighted and
controlled for the complex design of the survey (i.e., clustering, stratification, weighting). Anal-
yses incorporated the use of a finite population correction (FPC) factor to account for the large
sampling fraction. The chi-squared tests incorporated a Rao-Schott second order correction to
account for the survey design. Differences in age (natural log transformed) and CD4 (square
root transformed) were assessed using survey adjusted t-tests.
Funding and Ethical Review
Funding for this study was provided by the U.S. President’s Emergency Plan for AIDS Relief
through Cooperative Agreement 5U19GH000041 from CDC and by the United States Agency
for International Development. Ethical approval was obtained from the KEMRI Ethical Review
Committee and the CDC Institutional Review Board. We received a waiver of formal written
informed consent for participation in this study because (1) the data and specimen collection
were not experimental (i.e. they were already recommended as part of Kenyan national guide-
lines for care of PLHIV); (2) the study activities posed no more than minimal risk to study par-
ticipants; (3) participation did not adversely affect the welfare or rights of the patients in any
way; and (4) to require formal written consent would have imposed an undue burden on the
clinical staff of these busy clinics.
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Results
Between May 2011 and June 2012, 1,157 PLHIV were enrolled in HIV care and treatment at
the 15 study sites. Of these, 880 (76.1%) were eligible for enrollment, of which 862 (98.0%)
were enrolled (Fig 1). After enrollment, 84 (9.7%) PLHIV were determined to be ineligible or
Fig 1. Flow Diagram Showing Numbers of People Living with HIV (PLHIV) Screened, Eligible,
Enrolled, and Included in the Analysis.
doi:10.1371/journal.pone.0167685.g001
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withdrew. An additional 40 (5.1%) PLHIV were excluded because they did not have two valid
test results for their sputum specimens, leaving 738 PLHIV for the analysis. No adverse events
were reported as part of this study.
Among PLHIV evaluated for TB at enrollment into HIV services, 83 [11.2%; 95% confi-
dence interval (95% CI), 9.9–12.7]) were diagnosed with bacteriologically-confirmed pulmo-
nary TB. The median age of enrolled PLHIV was 30 years (interquartile range, 24–39); 20
(2.7%; 95% CI, 2.1–3.4) PLHIV were younger than 15 years and 487 PLHIV (66.1%; 95% CI,
61.7–70.2) were female. The median CD4+ cell count was 343 per μL (interquartile range,
168–518). Compared to PLHIV in whom no TB diagnosis was made, PLHIV with TB disease
had a significantly lower median CD4+ cell count and were significantly more likely to have
an abnormal chest radiograph at enrollment (Table 1).
Performance of the WHO Screening Algorithm among All PLHIV
Enrolling in HIV Care
Documentation of TB screening using the WHO screening algorithm was complete for 696
[94.3% (unweighted proportion)] of 738 PLHIV. Overall, 53.2% of PLHIV screened at
enrollment reported having at least one symptom in the WHO screening algorithm
(Table 2). Among PLHIV with TB disease, 74.1% [95% CI, 64.1–82.2] had a positive WHO
symptom screen (90.3% [95% CI, 79.1–95.8] for smear-positive TB disease and 63.0% [95%
CI, 54.3–70.9] for smear-negative disease) compared to 50.5% [95% CI, 46.1–54.9] PLHIV
who did not have TB. Weight loss in the previous 4 weeks and fever were commonly reported
symptoms among all PLHIV [34% (95%CI, 28.8–39.6) and 33.6% (95% CI, 29.6–37.9),
respectively] and among PLHIV with TB [57.6% (95% CI, 48.8–66.0) and 54.3% (95% CI,
44.3–64.0), respectively]. Current cough was reported by 42.7% (95% CI, 33.4–52.7) of
PLHIV with TB disease compared to 24.7% (95% CI, 21.1–28.8) of PLHIV without TB dis-
ease (Table 1).
Among 696 PLHIV with documentation of WHO screening, 539 [77.4% (unweighted
proportion)] received chest radiography. Adding a chest radiograph to the screening algo-
rithm so that PLHIV with any symptom or an abnormal chest radiograph were classified as
screening positive increased sensitivity compared to WHO symptom screening alone [90.9%
(95% CI, 86.4–93.9) versus 74.1% (95% CI, 64.1–82.2)], slightly increased negative predictive
value [96.1% (95% CI, 94.4–97.3) versus 93.8% (95% CI, 91.4–95.6)], but decreased specific-
ity [32.0% (95% CI, 27.5–36.8) versus 49.5% (95% CI, 45.1–53.9)] (Table 2). Among PLHIV
with a CD4+ cell count below 100 cells/μL at enrollment, the WHO screening algorithm had
a sensitivity of 92.6% (95% CI, 83.8–96.8), although specificity decreased to 24.3% (95% CI,
20.3–28.9) and negative predictive value decreased to 90.6% (95% CI, 78.9–96.2) (data not
shown).
Performance of Kenya MOH and ID-TB/HIV Clinical Screening
Algorithms among All PLHIV Enrolling in HIV Care
Overall, 50.1% of all PLHIV reported having at least one of the symptoms in the MOH TB
screening algorithm, with weight loss remaining the most commonly reported symptom
(66.0% of PLHIV). This algorithm performed as follows: sensitivity 77.5% (95% CI, 68.6–84.5),
specificity 49.4% (95% CI, 43.3–55.5), and negative predictive value of 94.7% (95% CI, 92.9–
96.0). The ID-TB/HIV algorithm performed similarly, with a sensitivity of 72.5% (95% CI,
60.9–81.7), specificity 56.5% (95% CI, 52.5–60.5), and negative predictive value of 94.3% (95%
CI, 91.6–96.2) [data not shown].
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Table 1. Characteristics of People Living with HIV (PLHIV) According to Tuberculosis (TB) Diagnosis.
Characteristic All PLHIV
(N = 738), % [95%
CI]
TB Prevalence, %
[95% CI]
TB Diagnosed (n = 83, 11.2%
[9.9, 12.7]), Column % [95%
CI]
TB Not Diagnosed (n = 656,
88.8% [87.3, 90.1]), Column %
[95% CI]
P value
Median age (IQR) 30 (24–39) - - - - 32 (25–40) 29 (24–39) 0.668
<15 (n = 20) 2.7 [2.1,3.4] 20.1 [11.1, 33.5] 4.8 [2.4, 9.2] 2.4 [1.8, 3.2]
15–24 (n = 170) 23.1 [20.7, 25.8] 7.1 [5.2, 9.5] 14.5 [11.5, 18.2] 24.2 [21.5, 27.1]
25–29 (n = 177) 24 [21.8, 26.4] 10.7 [8.1, 14.0] 22.9 [18.1, 28.6] 24.2 [21.9, 26.6]
30–39 (n = 195) 26.5 [24.1, 29.0] 13.8 [11.7, 16.3] 32.6 [26.8, 38.8] 25.7 [23.6, 28.0]
40–49 (n = 91) 12.3 [10.2, 14.8] 15.4 [11.1, 20.9] 16.8 [11.1, 24.6] 11.7 [9.6, 14.2]
50+ (n = 85) 11.4 [9.5, 13.7] 8.3 [4.5, 14.8] 8.4 [4.8, 14.5] 11.8 [9.7, 14.3]
Sex
Male (n = 251) 33.9 [29.8, 38.3] 13.6 [11.4, 16.1] 40.9 [33.8, 48.4] 33 [28.9, 37.3] 0.007
Female (n = 487) 66.1 [61.7, 70.2] 10.1 [8.6, 11.8] 59.1 [51.6, 66.2] 67 [62.7, 71.1]
Pregnant Women†
Yes (n = 134) 29.2 [21.8, 37.8] 5.9 [3.6, 9.7] 17.5 [9.7, 29.7] 30.4 [22.8, 39.3] 0.004
No (n = 332) 70.8 [62.2, 78.2] 11.5 [9.6, 13.7] 82.5 [70.3, 90.3] 69.6 [60.7, 77.2]
Median CD4 count (IQR)‡ 343 [168, 518] - - - - 164 [73, 311] 360 [197, 536] <0.001
<100 (n = 111) 16.1 [14.0, 18.5] 25.1 [19.7, 31.4] 35.7 [29.9, 42.0] 13.6 [11.3, 16.3]
100–199 (n = 87) 12.7 [11.1, 14.4] 18.5 [14.4, 23.5] 20.7 [14.5, 28.6] 11.6 [10.2, 13.3]
200–349 (n = 152) 22 [20.6, 23.5] 9.9 [7.0, 13.8] 19.3 [14.5, 25.2] 22.4 [20.9, 23.9]
350–499 (n = 153) 22.1 [20.4, 24.0] 6.6 [4.0, 10.5] 12.8 [81, 19.6] 23.3 [21.5, 25.3]
> = 500 (n = 187) 27.1 [25.3, 28.9] 4.8 [3.2, 7.1] 11.4 [8.0, 16.1] 29.1 [26.9, 31.3]
Symptoms in World Health
Organization algorithm§
Current cough (n = 173) 24.7 [21.1, 28.8] 18.6 [15.7, 21.8] 42.7 [33.4, 52.7] 22.6 [19.3, 26.2] <0.001
No current cough (n = 526) 75.3 [71.2, 78.9] 8.2 [6.6, 10.1] 57.3 [47.3, 66.6] 77.4 [73.8, 80.7]
Fever in previous 4 weeks
(n = 240)
33.6 [29.6, 37.9] 17.9 [15.6, 20.5] 54.3 [44.3, 64.0] 31 [27.4, 34.8] <0.001
No fever in previous 4 weeks
(n = 472)
66.4 [62.1, 70.4] 7.6 [5.9, 9.8] 45.7 [36.0, 55.7] 69 [65.2, 72.6]
Night sweats in previous 4 weeks
(n = 185)
26.2 [22.0, 30.8] 19.5 [16.1, 23.4] 46.3 [34.8,58.2] 23.7 [19.9,27.9] <0.001
No night sweats in previous 4
weeks (n = 522)
73.8 [69.2, 78.0] 8 [6.2, 10.3] 53.7 [41.8,65.2] 76.3 [72.1,80.1]
Weight loss in previous 4 weeks
(n = 244)
34 [28.8,39.6] 18.5 [15.2,22.3] 57.6 [48.8,66.0] 31.1 [25.9,36.8] <0.001
No weight loss in previous 4
weeks (n = 471)
66 [60.4,71.2] 7 [5.7,8.6] 42.4 [34.0,51.2] 68.9 [63.2,74.1]
Any lymphadenopathy€
Yes (n = 36) 5.1 [3.7, 7.0] 16.9 [10.8, 25.4] 7.6 [5.1, 11.2] 4.7 [3.2, 6.9] 0.074
No (n = 669) 94.9 [93.0, 96.3] 10.9 [9.3, 12.7] 92.4 [88.8, 94.9] 95.3 [93.1, 96.8]
Chest radiograph**
Normal (n = 319) 55.8 [47.5, 63.7] 5.4 [4.0, 7.2] 24.3 [17.8, 32.2] 60.2 [51.1, 68.6] <0.001
Abnormal (n = 253) 44.2 [36.3, 52.5] 21 [17.1, 25.5] 75.7 [67.8, 82.2] 39.8 [31.2, 48.9]
Abnormal chest radiograph§§
Consistent with TB (n = 102) 41.3 [34.9, 47.9] 39.2 [31.0, 48.1] 75.5 [65.2, 83.6] 31.9 [24.9, 39.9] <0.001
(Continued )
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Screening for TB among Pregnant Women Enrolling in PMTCT Services
Among the 487 women enrolled in this study, 134 (27.5%) were pregnant women identified at
enrollment into PMTCT services. These pregnant women represented 18.2% of all PLHIV in
this study and had a median age of 25 years (interquartile range, 22–29). TB prevalence among
pregnant women was lower than among both non-pregnant women and men [5.9% (95% CI,
3.6–9.7) versus 11.5% (95% CI, 9.6–13.7) and 13.6% (95% CI, 11.4–16.1), respectively]. Preg-
nant women with TB did not have a significantly different baseline median CD4+ cell count
(377cells/μL; IQR, 165–609cells/μL) than pregnant women without TB (401 cells/μL; IQR, 255,
637 cells/μL). Only 33 (24.6%) pregnant women reported having at least one of the symptoms
in the WHO screening algorithm compared to 195 (55.2%) non-pregnant women and 143
(57.0%) men; night sweats was most commonly reported [57.6% (95% CI, 47.4–67.0) of symp-
tomatic pregnant women] and weight loss was least commonly reported [36.1% (95% CI,
26.1–48.6) of symptomatic pregnant women]. The sensitivity of the WHO algorithm was sig-
nificantly lower among pregnant women, 28.2% [95% CI, 14.9–46.7] compared to 78.3% [95%
CI, 67.3–86.4] for non-pregnant women and 77.2% [95% CI, 68.3–84.2] for men (Table 2).
Discussion
In this study, the prevalence of bacteriologically-confirmed TB among PLHIV enrolling in
HIV services was 11.2%. This is consistent with findings from a multi-country study that
found a 12% TB prevalence among PLHIV not on ART in four countries in sub-Saharan
Africa [10]; the TB prevalence is lower than the 15% TB prevalence among PLHIV in three
countries in Southeast Asia in the ID-TB/HIV study, but this may also be related to the lower
initial median CD4+ cell count in that study (242 cells/ μL) [12]. In our study population, the
three clinical screening algorithms performed similarly and the WHO clinical screening algo-
rithm performed as expected among all PLHIV, given the TB prevalence [4, 5]. However, the
performance of clinical screening was variable across several sub-sets of PLHIV, including
those who were severely immunosuppressed and pregnant women accessing PMTCT services,
which has important programmatic implications.
The prevalence of TB varied across the districts, and likely reflects the burden of disease in
those districts. Given the substantial burden of TB among PLHIV at enrollment in HIV care,
TB case finding should be a priority intervention in HIV care and treatment and PMTCT set-
tings. Although implementation of routine ICF is expanding, only 7 million (19%) of the 36.9
million PLHIV worldwide in 2014 were reported to be screened for TB [2, 21]. Our study
Table 1. (Continued)
Characteristic All PLHIV
(N = 738), % [95%
CI]
TB Prevalence, %
[95% CI]
TB Diagnosed (n = 83, 11.2%
[9.9, 12.7]), Column % [95%
CI]
TB Not Diagnosed (n = 656,
88.8% [87.3, 90.1]), Column %
[95% CI]
P value
Not Consistent with TB (n = 146) 58.7 [52.1, 65.1] 8.9 [5.7, 13.6] 24.5 [16.4, 34.8] 68.1 [60.1, 75.1]
*The n reported for each characteristic refers to PLHIV and is not provided for each column
† Excludes 21 women whose pregnancy status was unknown
‡Excludes 48 people with missing CD4 count at enrollment, 5 of whom were diagnosed with TB and 44 of whom did not have TB
§ Excludes 39 PLHIV without assessment of current cough, 26 PLHIV without assessment of fever in the previous 4 weeks, 31 PLHIV without assessment
of night sweats in the previous 4 weeks, and 23 PLHIV without assessment of weight loss in the previous 4 weeks
€ Excludes 33 PLHIV in whom lymphadenopathy was not assessed
** Excludes 166PLHIV who did not have a chest radiograph, including 134 pregnant women who were not referred for chest radiography
§§ Excludes 5 PLHIV with abnormal chest radiographs which were not classified as consistent or not consistent with TB
doi:10.1371/journal.pone.0167685.t001
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demonstrates that half of all PLHIV newly enrolling in HIV care services reported at least one
TB symptom. However, only 15% of symptomatic PLHIV were diagnosed with pulmonary
TB, meaning that the majority of PLHIV identified with presumptive TB were not TB cases.
Additionally, if TB diagnostic testing were limited to PLHIV reporting symptoms in the WHO
algorithm, 25% of all PLHIV with bacteriologically-confirmed pulmonary TB would have been
missed. According to WHO guidelines, these asymptomatic PLHIV with TB disease would
be candidates for isoniazid preventive therapy, meaning that they would have erroneously
received monotherapy instead of the recommended four-drug TB treatment regimen. Repeat
clinical screening is recommended for all PLHIV receiving isoniazid preventive therapy to
identify those with TB disease who are missed on an initial screen; however, most studies of
intensified case finding, including ours, have reported on the yield at entry into HIV services
making evidence about the performance of clinical screening during repeat clinical visits
limited.
Table 2. Performance of World Health Organization (WHO) Tuberculosis (TB) Intensified Case Finding Algorithm in People Living with HIV
(PLHIV) in Kenya.
Percent
Screening
Positive [95%
CI]
Sensitivity
[95% CI]
Specificity
[95% CI]
Negative
Predictive Value
[95% CI]
Positive
Predictive
Value [95% CI]
Likelihood Ratio
Positive [95%
CI]
Likelihood Ratio
Negative [95%
CI]
WHO Algorithm* 53.2 [48.5,57.8] 74.1
[64.1,82.2]
49.5
[45.1,53.9]
93.8 [91.4,95.6] 15.6 [13.8,17.7] 1.47 [1.38, 1.57] 0.53 [0.40, 0.68]
WHO Algorithm + Chest
Radiograph†
70.8 [66.5,74.8] 90.9
[86.4,93.9]
32 [27.5,36.8] 96.1 [94.4,97.3] 15.8 [13.3,18.6] 1.34 [1.25, 1.42] 0.29 [0.20, 0.41]
WHO Algorithm
+ Contact with TB case‡
53.6 [47.5,59.6] 77.5
[68.6,84.5]
49.4
[43.3,55.5]
94.7 [92.9,96.0] 15.9 [13.6,18.6] 1.53 [1.44, 1.63] 0.46 [0.36, 0.58]
WHO Algorithm
Performance for Age<
15 years§
84.7 [72.3,92.2] 100 - - 19.4
[9.6,35.3]
100 - - 24.9 [13.5,41.4] 1.24 [1.07, 1.43] - -
WHO Algorithm
Performance for Adults
( 15 years)§
52.3 [47.7,56.9] 72.8
[62.8,80.9]
50.2
[45.8,54.6]
93.8 [91.3,95.5] 15.2 [13.2,17.5] 1.46 [1.36, 1.57] 0.54 [0.43, 0.69]
WHO Algorithm
Performance for PLHIV
with CD4 < 350€
67.7 [63.5,71.6] 77.6
[68.7,84.5]
34.3
[30.5,38.3]
88.5 [84.2,91.8] 19 [16.0,22.4] 1.18 [1.09, 1.28] 0.65 [0.49, 0.87]
WHO Algorithm
Performance for PLHIV
with CD4350 €
39.7 [34.5,45.2] 57.6
[41.8,72.0]
61.4
[56.2,66.3]
95.9 [93.3,97.5] 8.5 [6.4,11.2] 1.49 [1.26, 1.72] 0.69 [0.52, 0.91]
WHO Algorithm
Performance Stratified
by Sex and Pregnancy¥
Pregnant Women 25.6 [19.7,32.5] 28.2
[14.9,46.7]
74.6
[67.6,80.4]
94.8 [90.4,97.3] 5.9 [2.8,11.9] 1.11 [0.68, 1.80] 0.96 [0.80, 1.17]
Non-Pregnant Women 58.1 [54.4,61.8] 78.3
[67.3,86.4]
44.5
[40.9,48.3]
93.9 [90.3,96.2] 15.8 [13.0,19.0] 1.41 [1.26, 1.58] 0.49 [0.33, 0.72]
Men 61.8 [56.7,66.6] 77.2 [68.3,
84.2]
40.6 [35.4,
46.1]
92.0 [88.1, 94.6] 16.8 [14.1,20.0] 1.30 [1.16, 1.46] 0.56 [0.41, 0.78]
*Excludes 42 people with incomplete TB symptom screening data
† Excludes 42 people with incomplete TB symptom screening data and an additional 157 with no chest radiograph (including all 134 pregnant women)
‡ Excludes 42 people with incomplete TB symptom screening data and an additional 7 with no data on TB contact
§ Excludes 1 child younger than 15 years and 42 adults with incomplete TB symptom screening data and an additional 47 adults with missing CD4 count at
enrollment
€ Excludes 42 people with incomplete TB symptom screening data and an additional 19 with missing pregnancy status
doi:10.1371/journal.pone.0167685.t002
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Our results confirm that the performance of the WHO TB ICF algorithm varies with the
level of immunocompromise [22, 23]. Clinical screening was more sensitive for TB case find-
ing among PLHIV with a CD4+ count below 100 cells/μL at enrollment, identifying more than
92% of these PLHIV with TB disease as needing a diagnostic evaluation. Because CD4 count
results are not available in all settings or are often received after the patient’s first visit to the
HIV care and treatment clinic, the utility of CD4 count for identifying priority populations for
clinical TB screening or for prioritizing PLHIV with presumptive TB for diagnostic evaluation
is limited.
Approximately two-thirds of PLHIV enrolled in this study were women, which is consistent
with findings from a review of ART programs which found that the female-to-male new ART
enrollee ratios were 2.10 in countries in East Africa, partially because of access to HIV testing
and ART as part of antenatal services for pregnant women [24]. Our study found that clinical
TB screening was particularly ineffective for TB case finding among pregnant women access-
ing PMTCT services. Half as many pregnant women reported TB symptoms at enrollment in
HIV care as other PLHIV; if TB diagnostic testing were limited to pregnant women reporting
symptoms in the WHO algorithm, more than two-thirds of laboratory-confirmed pulmonary
TB would have been missed. These findings are consistent with data from other studies of TB
screening among pregnant women living with HIV [11, 25–28]. One possible explanation for
this difference is that pregnancy “masks” the symptoms of TB, making common TB symptoms
such as weight loss less evident [29]. Indeed, weight loss was the least commonly reported
symptom among pregnant women despite being the most commonly reported symptom for
all PLHIV. An additional possibility is that pregnant women with TB were screened and tested
at an earlier stage of disease than non-pregnant women. Screening tools and diagnostic tests
are expected to have lower sensitivity in early- stage disease than in late-stage disease [30].
Although we did not assess reasons for seeking care, PLHIV who were not pregnant may have
presented for clinical attention because they were feeling unwell, whereas pregnant women
more likely sought clinical care for their pregnancy. If this hypothesis were true, then the dif-
ference in sensitivity observed could be due to the different average stage of TB disease present
in the two groups. Ultimately, given the unreliability of symptom-based TB screening among
HIV-infected pregnant women, alternative strategies, such as Xpert MTB/RIF testing for all
pregnant women, are warranted [31]. The high prevalence of TB in our population, combined
with the sub-optimal sensitivity of symptom-based screening, would suggest that such a strat-
egy could be considered for the initial evaluation of all patients with HIV.
In this study, TB prevalence among pregnant women living with HIV was approximately
half that of non-pregnant women and men living with HIV. National TB surveillance systems
do not routinely report pregnancy status of TB cases. However, a recent study estimated that
the global burden of TB in pregnancy was substantial, with 216,500 cases in 2011, 41% of
which occurred in the WHO AFRO region [32]. Data from the United Kingdom show that TB
incidence in the postpartum period is significantly higher than among pregnant women or
non-pregnant women outside of the postpartum period, potentially reflecting delays in diag-
nosis during pregnancy due to diagnostic challenges and immunologic changes [33]. Partially
due to the lower prevalence of TB among pregnant women, the negative predictive value of the
WHO TB ICF algorithm was comparable among pregnant women and other PLHIV.
Strategies to optimize the performance of TB screening include expanding the number of
symptoms and signs included in the screening algorithm, assessing for TB contact status, and
adding chest radiograph. In our study, we found that the Kenya MOH TB screening algorithm,
which included a combination of six symptoms and close contact with a person with TB dis-
ease, only marginally increased sensitivity, suggesting that expanded clinical screening likely
has limited value. Including chest radiography as part of the WHO symptom screening
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algorithm improved case finding and should be considered as feasible, keeping in mind that
this increase in sensitivity was associated with a decrease in specificity. This decrease in speci-
ficity is not surprising given that PLHIV commonly have non-TB related lung changes which
in some cases can complicate radiologic TB diagnosis, especially in early stages of disease [23].
This study had multiple limitations. Symptom screening was conducted as part of routine
clinical services and clinical symptoms were not independently verified by study staff. Addi-
tionally, under these routine practice conditions, we were unable to obtain complete data on
all patients. Clinical information, such as baseline CD4+ cell count and chest radiograph
results, was missing for a subset of patients. Approximately 5% of PLHIV enrolled in the study
were excluded from the final analysis because they were unable to provide more than one spu-
tum specimen or provided specimens that could not be examined due to culture contamina-
tion. Of the 40 excluded PLHIV, 2 (5%) were found to have TB disease by Xpert MTB/RIF or
culture of one sputum specimen; exploratory analysis with differing exclusion criteria did not
result in substantive differences in the performance of the clinical screening algorithms (data
not shown). However, the true prevalence of TB among the other PLHIV with culture contam-
ination is unknown. Finally, while our study was designed to be representative of the Kisumu,
Siaya, and Bondo Districts of Kenya as defined at the time of study inception, our study was
not designed to be nationally-representative or generalizable to other settings in Kenya or sub-
Saharan Africa.
This study confirms that the WHO TB ICF algorithm performs as predicted among PLHIV
newly enrolling in HIV services in this high HIV and TB burden region of Kenya. However, as
half of all PLHIV reported symptoms consistent with TB disease, use of this clinical screening
algorithm would lead to diagnostic evaluation of a large number of PLHIV without TB disease
and would additionally miss asymptomatic PLHIV with TB disease. Given the poor perfor-
mance of clinical screening among pregnant women, national HIV and PMTCT programs
should evaluate the programmatic feasibility and cost implications of laboratory-based screen-
ing for TB disease at the initial presentation for HIV care, such as requesting a single Xpert
MTB/RIF test for all HIV-infected pregnant women and potentially all PLHIV, enrolling in
HIV services. Additional analyses are needed to determine the performance of WHO screen-
ing at follow-up visits, strategies to improve the sensitivity and negative predictive value of
clinical screening algorithms, optimal intervals for screening, and to assess whether different
clinical or laboratory-based (e.g. Xpert MTB/RIF) screening algorithms are more sensitive
among pregnant women living with HIV.
Acknowledgments
The authors would like to thank the dedicated healthcare workers at the HIV care and treat-
ment sites described in this evaluation, the laboratory personnel working at the Kenya Medical
Research Institute/CDC reference laboratory as well as additional Kenya Medical Research
Institute personnel, including the study coordinators (Mr. Bernard Ochuka and Ms. Cynthia
Ogwang), data abstraction team, and the field site supervisors who made this study possible.
Additionally, the authors also thank the Kenya MOH (Division of Leprosy, Tuberculosis and
Lung Disease and the National AIDS and STI Control Program) and the Director of the Kenya
Medical Research Institute for collaboration in this study.
Disclaimer
The findings and conclusions in this reports are those of the authors and do not necessarily
represent the official position of the U.S. Centers for Disease Control and Prevention or the
Government of Kenya.
TB Screening for People Living with HIV
PLOS ONE | DOI:10.1371/journal.pone.0167685 December 9, 2016 11 / 14
Author Contributions
Conceptualization: SM JSC RWS HLA KDM AN KPC.
Data curation: RWS.
Formal analysis: RWS CMH SM JSC.
Funding acquisition: AN KPC.
Investigation: SM JSC HLA KDM BB.
Methodology: SM JSC RWS HLA KDM AN KPC.
Project administration: SM JSC BB.
Supervision: HM AN KPC.
Visualization: SM.
Writing – original draft: SM.
Writing – review & editing: SM JSC RWS HLA KDM BB HM CMH AN KPC.
References
1. UNAIDS. The Gap Report. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS,
2014.
2. World Health Organization. Global Tuberculosis Report 2015. Geneva, Switzerland: World Health
Organization, 2015.
3. World Health Organization. WHO policy on collaborative TB/HIV activities guidelines for national pro-
grammes and other stakeholders. Geneva, Switzerland: World Health Organization, 2012.
4. Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H, Cain KP, et al. Development of a standard-
ized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual
participant data meta-analysis of observational studies. PLoS medicine. 2011; 8(1):e1000391. doi: 10.
1371/journal.pmed.1000391 PMID: 21267059
5. World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive
therapy for people living with HIV in resourceconstrained settings. Geneva, Switzerland: World Health
Organization, 2011.
6. Kufa T, Mngomezulu V, Charalambous S, Hanifa Y, Fielding K, Grant AD, et al. Undiagnosed tuberculo-
sis among HIV clinic attendees: association with antiretroviral therapy and implications for intensified
case finding, isoniazid preventive therapy, and infection control. Journal of acquired immune deficiency
syndromes. 2012; 60(2):e22–8. Epub 2012/05/26. doi: 10.1097/QAI.0b013e318251ae0b PMID:
22627184
7. Lawn SD, Kranzer K, Edwards DJ, McNally M, Bekker LG, Wood R. Tuberculosis during the first year of
antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. Aids.
2010; 24(9):1323–8. doi: 10.1097/QAD.0b013e3283390dd1 PMID: 20386425
8. Lawn SD, Kranzer K, Edwards DJ, Wood R. Screening for active tuberculosis among patients access-
ing antiretroviral therapy in sub-Saharan Africa. The international journal of tuberculosis and lung dis-
ease: the official journal of the International Union against Tuberculosis and Lung Disease. 2009; 13
(9):1186–7; author reply 7–8.
9. Rangaka MX, Wilkinson RJ, Glynn JR, Boulle A, van Cutsem G, Goliath R, et al. Effect of antiretroviral
therapy on the diagnostic accuracy of symptom screening for intensified tuberculosis case finding in a
South African HIV clinic. Clinical infectious diseases: an official publication of the Infectious Diseases
Society of America. 2012; 55(12):1698–706. Epub 2012/09/08.
10. Swindells S, Komarow L, Tripathy S, Cain KP, MacGregor RR, Achkar JM, et al. Screening for pulmo-
nary tuberculosis in HIV-infected individuals: AIDS Clinical Trials Group Protocol A5253. The interna-
tional journal of tuberculosis and lung disease: the official journal of the International Union against
Tuberculosis and Lung Disease. 2013; 17(4):532–9.
11. LaCourse SM, Cranmer LM, Matemo D, Kinuthia J, Richardson BA, John-Stewart G, et al. Tuberculosis
Case Finding in HIV-Infected Pregnant Women in Kenya Reveals Poor Performance of Symptom
TB Screening for People Living with HIV
PLOS ONE | DOI:10.1371/journal.pone.0167685 December 9, 2016 12 / 14
Screening and Rapid Diagnostic Tests. Journal of acquired immune deficiency syndromes. 2016; 71
(2):219–27. doi: 10.1097/QAI.0000000000000826 PMID: 26334736
12. Cain KP, McCarthy KD, Heilig CM, Monkongdee P, Tasaneeyapan T, Kanara N, et al. An algorithm for
tuberculosis screening and diagnosis in people with HIV. The New England journal of medicine. 2010;
362(8):707–16. doi: 10.1056/NEJMoa0907488 PMID: 20181972
13. Division of Leprosy, Tuberculosis, and Lung Diseases. Guidelines on Management of Leprosy and
Tuberculosis, September 2009 Version. Nairobi, Kenya: Kenya Ministry of Public Health and Sanita-
tion, 2009.
14. Cavanaugh JS, Modi S, Musau S, McCarthy K, Alexander H, Burmen B, et al. Comparative Yield of Dif-
ferent Diagnostic Tests for Tuberculosis among People Living with HIV in Western Kenya. PloS one.
2016; 11(3):e0152364. doi: 10.1371/journal.pone.0152364 PMID: 27023213
15. National AIDS and STI Control Programme, Ministry of Public Health and Sanitation, Kenya. Guidelines
for HIV Testing and Counselling and Kenya. Nairobi, Kenya: NASCOP, 2008.
16. Kenya National AIDS and STI Control Programme. Guidelines for Antiretroviral Drug Therapy in Kenya.
In: Programme NAaSC, editor. Third Edition ed. Nairobi, Kenya: Kenya Ministry of Public Health and
Sanitation; 2005.
17. Kenya National AIDS and STI Control Programme. Guidelines for Antiretorviral Therapy in Kenya. Nai-
robi, Kenya: Kenya Ministry of Medical Services, 2011.
18. World Health Organization. WHO Policy Update: Xpert MTB/RIF Assay for the Diagnosis of Pulmonary
and Extrapulmonary TB in Adults and Children. Geneva, Switzerland: World Health Organization,
2014.
19. Siddiqui S, Ru¨sch-Gerdes S. MGIT Procedure Manual. Geneva, Switzerland: Foundation for Innova-
tive New Diagnostics, 2006.
20. World Health Organization. Definitions and Reporting Framework for Tuberculosis– 2013 Revision.
Geneva, Switzerland: World Health Organization, 2013.
21. UNAIDS. How AIDS Changed Everything—Fact Sheet: 2014 Global Statistics. Geneva, Switzerland:
Joint United Nations Programme on HIV/AIDS, 2014.
22. Ahmad Khan F, Verkuijl S, Parrish A, Chikwava F, Ntumy R, El-Sadr W, et al. Performance of symp-
tom-based tuberculosis screening among people living with HIV: not as great as hoped. Aids. 2014; 28
(10):1463–72. doi: 10.1097/QAD.0000000000000278 PMID: 24681417
23. Lawn SD, Wood R. Tuberculosis in antiretroviral treatment services in resource-limited settings:
addressing the challenges of screening and diagnosis. The Journal of infectious diseases. 2011; 204
Suppl 4:S1159–67.
24. Auld AF, Shiraishi RW, Mbofana F, Couto A, Fetogang EB, El-Halabi S, et al. Lower Levels of Antiretro-
viral Therapy Enrollment Among Men with HIV Compared with Women—12 Countries, 2002–2013.
MMWR Morb Mortal Wkly Rep. 2015; 64(46):1281–6. doi: 10.15585/mmwr.mm6446a2 PMID:
26605861
25. Gounder CR, Wada NI, Kensler C, Violari A, McIntyre J, Chaisson RE, et al. Active tuberculosis case-
finding among pregnant women presenting to antenatal clinics in Soweto, South Africa. Journal of
acquired immune deficiency syndromes. 2011; 57(4):e77–84. doi: 10.1097/QAI.0b013e31821ac9c1
PMID: 21436710
26. Gupta A, Chandrasekhar A, Gupte N, Patil S, Bhosale R, Sambarey P, et al. Symptom screening
among HIV-infected pregnant women is acceptable and has high negative predictive value for active
tuberculosis. Clinical infectious diseases: an official publication of the Infectious Diseases Society of
America. 2011; 53(10):1015–8.
27. Hoffmann CJ, Variava E, Rakgokong M, Masonoke K, van der Watt M, Chaisson RE, et al. High preva-
lence of pulmonary tuberculosis but low sensitivity of symptom screening among HIV-infected pregnant
women in South Africa. PloS one. 2013; 8(4):e62211. Epub 2013/04/25. doi: 10.1371/journal.pone.
0062211 PMID: 23614037
28. Kosgei RJ, Szkwarko D, Callens S, Gichangi P, Temmerman M, Kihara AB, et al. Screening for tubercu-
losis in pregnancy: do we need more than a symptom screen? Experience from western Kenya. Public
Health Action. 2013; 3(4):294–8. doi: 10.5588/pha.13.0073 PMID: 26393049
29. Getahun H, Sculier D, Sismanidis C, Grzemska M, Raviglione M. Prevention, diagnosis, and treatment
of tuberculosis in children and mothers: evidence for action for maternal, neonatal, and child health ser-
vices. The Journal of infectious diseases. 2012; 205 Suppl 2:S216–27.
30. Lawn SD, Kerkhoff AD, Vogt M, Wood R. HIV-associated tuberculosis: relationship between disease
severity and the sensitivity of new sputum-based and urine-based diagnostic assays. BMC medicine.
2013; 11:231. doi: 10.1186/1741-7015-11-231 PMID: 24168211
TB Screening for People Living with HIV
PLOS ONE | DOI:10.1371/journal.pone.0167685 December 9, 2016 13 / 14
31. Turnbull ER, Kancheya NG, Harris JB, Topp SM, Henostroza G, Reid SE. A model of tuberculosis
screening for pregnant women in resource-limited settings using Xpert MTB/RIF. J Pregnancy. 2012;
2012:565049. doi: 10.1155/2012/565049 PMID: 22007302
32. Sugarman J, Colvin C, Moran AC, Oxlade O. Tuberculosis in pregnancy: an estimate of the global bur-
den of disease. Lancet Glob Health. 2014; 2(12):e710–6. doi: 10.1016/S2214-109X(14)70330-4 PMID:
25433626
33. Zenner D, Kruijshaar ME, Andrews N, Abubakar I. Risk of tuberculosis in pregnancy: a national, primary
care-based cohort and self-controlled case series study. American journal of respiratory and critical
care medicine. 2012; 185(7):779–84. doi: 10.1164/rccm.201106-1083OC PMID: 22161161
TB Screening for People Living with HIV
PLOS ONE | DOI:10.1371/journal.pone.0167685 December 9, 2016 14 / 14
